Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Novo Nordisk CEO attends crisis talks with Danish PM amid Trump's Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.

Fortune

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump's Greenland Purchase Could Impact Drug Prices For Americans

President-elect Trump's interest in buying Greenland from Denmark could affect drug prices in the US.

Top News

Novo Nordisk faces stock market bloodbath after drug trial disappoints

Shares in Novo Nordisk plunged 20% on Friday.

Fortune

Ozempic May Face Investigation Over Vision-Threatening Condition In Some Patients

Danish health authorities asked the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition.

International Business Times

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

MarketBeat

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

Fortune

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

The Independent UK

Five things you should know about the HIV epidemic

It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.

The Conversation

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Kiplinger

Stock Market Today: The S&P 500 Reclaims the 6K Level

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Benzinga

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Fortune

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Get all your
news in one place.

100's of premium titles.
One news app.

Salon

Wegovy on sale in China, cheaper than US

The medication is currently available in 16 other countries

International Business Times

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

Barchart

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

The Independent UK

Drugmakers see stocks tank after RFK Jr is nominated to oversee health department

JP Morgan Chase analysts say they’re ‘not surprised’ sector has come ‘under pressure’ since Kennedy’s nomination

International Business Times

Obesity Drug Maker Novo Nordisk Posts Strong Profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

Fortune

Danish town where Ozempic is made has highest rates of overweight children in Denmark

Novo Nordisk faces a challenge turning around the fortunes of residents in a major Danish manufacturing hub.

Barchart

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

1 … 14 15 16 17

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.